Postpartum Depression Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts

The Postpartum Depression Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Postpartum Depression Market Size During the Forecast Period?
The market size for postpartum depression has seen a significant expansion in the past few years. It is projected to escalate from $12.15 billion in 2024, reaching $16.09 billion in 2025, with an impressive compound annual growth rate (CAGR) of 32.4%. The notable growth during the historic period is primarily due to increased awareness about maternal mental health, advancements in research, initiatives for public health, and a rise in screenings.

The market for postpartum depression is projected to experience robust growth in the coming years. It is expected to increase to $49.4 billion by 2029, with a compound annual growth rate (CAGR) of 32.4%. The anticipated expansion during this period can be associated with factors such as telehealth services, advancements in pharmacology, maternal mental health laws, and growth in the mental health workforce. Key trends that will characterize this period include integrated care models, peer support programs, applications related to perinatal mental health, and tools for mental health screening.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13024

What Are the High-Growth Segments in the Postpartum Depression Market?
The postpartum depression market covered in this report is segmented -

1) By Types: Postpartum Blues, Postpartum Anxiety, Postpartum Obsessive Compulsive Disorder, Postpartum Panic Disorder, Postpartum Post-Traumatic Stress Disorder, Postpartum Psychosis, Other Types
2) By Treatment: Psychotherapy, Medication, Supplements, Other Treatments
3) By Route of Administration: Oral, Parenteral, Other Route Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Postpartum Blues: Mild Emotional Disturbances, Short-term Mood Swings
2) By Postpartum Anxiety: Generalized Anxiety Disorder (GAD), Panic Attacks
3) By Postpartum Obsessive Compulsive Disorder: Intrusive Thoughts, Compulsive Behaviors
4) By Postpartum Panic Disorder: Sudden Panic Attacks, Physical Symptoms
5) By Postpartum Post-Traumatic Stress Disorder (PTSD): Trauma Response To Childbirth, Flashbacks And Anxiety
6) By Postpartum Psychosis: Hallucinations, Severe Mood Swings
7) By Other Types: Mixed Mood Disorders, Comorbid Conditions With Postpartum

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13024&type=smp

What Key Drivers Are Expected to Influence Future Postpartum Depression Market Growth?
The postpartum depression market is projected to expand due to an expected rise in instances of postpartum depression. Generally occurring after the birth of a child, postpartum depression is an excessive concern that can also result in physical symptoms. The condition often coexists with postnatal depression and postpartum anxiety and can start at any point within the first-year post-birth. A blend of psychotherapy (also known as mental health counseling), medications, or both are generally used to treat it. A notable example from February 2022 demonstrates this - a University of Virginia School of Medicine survey of 1.1 million women found that the risk of postpartum depression was greatest among first-time mothers, women under 25, and mothers of twins. Interestingly, 10% of women aged 18-24 reported the highest rate of symptoms, and 11.3% of twin mothers exhibited symptoms, compared to 8.3% of mothers of single children. This anticipated increase in postpartum depression cases is forecasted to drive the growth of the postpartum depression market. The postpartum depression market is also anticipated to be propelled by the increasing number of childbirths. The term childbirth signifies the moment when a baby is born from the mother's uterus, frequently via the vaginal canal. This growing childbirth rate could lead to a surge in the occurrence of postpartum depression, a widespread mental disorder affecting women post childbirth. Some of the typical symptoms include sadness, anxiety, fatigue, and difficulties in forming a bond with the infant. For instance, the Centers for Disease Control and Prevention reported in January 2023 that the United States had observed a 1% rise in recorded births (totaling 3,664,292) in comparison to the preceding year. This upsurge in childbirths is expected to fuel the postpartum depression market's growth.

Which Companies Hold the Largest Share Across Different Postpartum Depression Market Segments?
Major companies operating in the postpartum depression market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline LLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Viatris Inc., Northwell Health, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals PLC, Sage Therapeutics Inc.

What Trends Are Driving Growth in The Postpartum Depression Market?
Firms in the postpartum depression sector are concentrating on creating novel products to maintain their market presence. The dearth of effective treatment options has yielded a growing demand for rapid-acting treatments and inventive delivery of care for postpartum depression. For example, Biogen Inc., a biotechnology firm based in the US, and Sage Therapeutics Inc., a US-based biopharmaceutical firm, announced in February 2023, that the FDA (Food and Drug Administration) in the United States has accepted the filing of an NDA (new drug application) for zuranolone for use in treating MDD (major depressive disorder) and PPD (postpartum depression). Zuranolone is an under-investigation drug intended for use as a 14-day, daily, fast-acting oral treatment in individuals with MDD and PPD. Zuranolone, being a neuroactive steroid, behaves as a positive allosteric modulator of GABA-A receptors, a distinct mode of action. It is envisioned to function in individuals with depression by rapidly rectifying unbalanced neural networks to aid in the restoration of brain function. Zuranolone influences brain networks that manage mood, arousal, behavior, and cognition.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/postpartum-depression-global-market-report

What Are the Emerging Geographies for The Postpartum Depression Market Growth?
North America was the largest region in the postpartum depression market in 2024. The regions covered in postpartum depression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Postpartum Depression Market?
2. What is the CAGR expected in the Postpartum Depression Market?
3. What Are the Key Innovations Transforming the Postpartum Depression Industry?
4. Which Region Is Leading the Postpartum Depression Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.